These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 36561760)

  • 1. Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
    Karim QA; Archary D; Barré-Sinoussi F; Broliden K; Cabrera C; Chiodi F; Fidler SJ; Gengiah TN; Herrera C; Kharsany ABM; Liebenberg LJP; Mahomed S; Menu E; Moog C; Scarlatti G; Seddiki N; Sivro A; Cavarelli M
    Front Immunol; 2022; 13():1055042. PubMed ID: 36561760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
    Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
    J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers.
    Kayesu I; Mayanja Y; Nakirijja C; Machira YW; Price M; Seeley J; Siu G
    BMC Womens Health; 2022 Nov; 22(1):440. PubMed ID: 36357920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya.
    Jackson-Gibson M; Ezema AU; Orero W; Were I; Ohiomoba RO; Mbullo PO; Hirschhorn LR
    BMC Public Health; 2021 Jul; 21(1):1284. PubMed ID: 34210288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?
    Eakle R; Venter F; Rees H
    Retrovirology; 2018 Apr; 15(1):29. PubMed ID: 29609619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.
    Heffron R; McClelland RS; Balkus JE; Celum C; Cohen CR; Mugo N; Bukusi E; Donnell D; Lingappa J; Kiarie J; Fiedler T; Munch M; Fredricks DN; Baeten JM;
    Lancet HIV; 2017 Oct; 4(10):e449-e456. PubMed ID: 28732773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.
    Naicker CL; Mansoor LE; Dawood H; Naidoo K; Singo D; Matten D; Williamson C; Abdool Karim Q
    BMC Infect Dis; 2020 Jul; 20(1):532. PubMed ID: 32698772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PrEP as Peri-conception HIV Prevention for Women and Men.
    Heffron R; Pintye J; Matthews LT; Weber S; Mugo N
    Curr HIV/AIDS Rep; 2016 Jun; 13(3):131-9. PubMed ID: 26993627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
    Baeten JM; Heffron R; Kidoguchi L; Mugo NR; Katabira E; Bukusi EA; Asiimwe S; Haberer JE; Morton J; Ngure K; Bulya N; Odoyo J; Tindimwebwa E; Hendrix C; Marzinke MA; Ware NC; Wyatt MA; Morrison S; Haugen H; Mujugira A; Donnell D; Celum C;
    PLoS Med; 2016 Aug; 13(8):e1002099. PubMed ID: 27552090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis.
    Baeten J; Celum C
    Annu Rev Med; 2013; 64():219-32. PubMed ID: 23020883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Being able to do whatever you wanna do as a woman is important:" a qualitative exploration of contraception as a frame of reference for HIV prevention with PrEP.
    Murphy EC; Danvers A; Zamudio AR; Avila K; Proehl M; Gonzalez-Argoti T; Mantell JE; Bauman LJ; Dolan SM
    Reprod Health; 2022 Apr; 19(1):92. PubMed ID: 35392943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research.
    Irungu E; Khoza N; Velloza J
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):490-499. PubMed ID: 34719745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
    Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
    AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
    Velloza J; Heffron R
    Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for a health equity framework in next-generation pre-exposure prophylaxis implementation.
    Valente PK; Operario D; Rusley J; Bauermeister JA; Biello KB
    Lancet HIV; 2023 Apr; 10(4):e266-e268. PubMed ID: 36848924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.